TCD-717

TCD-717 is a small molecule inhibitor specifically targeting choline kinase alpha (CHKA), an enzyme upregulated in many cancers and implicated in tumorigenesis. By binding to a unique site on CHKA, distinct from the canonical choline-binding pocket, TCD-717 disrupts phosphatidylcholine biosynthesis and choline metabolism pathways critical for cancer cell proliferation. Preclinical studies have demonstrated potent antitumor activity with improved safety compared to earlier CHKA inhibitors. Developed by Traslational Cancer Drugs Pharma SL (TCD Pharma), TCD-717 has completed phase 1 clinical trials as an intravenous therapy for advanced solid tumors[1][2][3][4][5][6][7].

Other names

Choline kinase alpha inhibitor (iv, solid tumors)